Cancer research. Melanoma drug vindicates targeted approach.
Garber
Ken
K
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000378:metabolism / Q000627:therapeutic use*; D017321:Clinical Trials, Phase I as Topic; D006801:Humans; D008545:Melanoma / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism / Q000556:secondary; D050505:Mutant Proteins / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism; D004364:Pharmaceutical Preparations / Q000008:administration & dosage* / Q000378:metabolism; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D015398:Signal Transduction / Q000187:drug effects
D000970:Antineoplastic Agents; D050505:Mutant Proteins; D004364:Pharmaceutical Preparations; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf